Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.80 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.71 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.71 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | HTR2B | P41595 | 1/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.71 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.68 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.68 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| [11C]Phenethylguanidine SCHEMBL28305963 | 0.94 | HTR3A (0.71) | HTR3AADRA2AADRA2BLMNATSHR | |
| [11C]Phenethylguanidine SCHEMBL11556997 | 0.90 | HTR3A (0.67) | HTR3AADRA2AADRA2BLMNATSHR | |
| SCHEMBL5840017 | 0.89 | HTR3A (1.00) | HTR3AADRA2AADRA2BLMNATSHR | |
| Phenformin SCHEMBL8425 | 0.84 | LMNA (1.00) | HTR3AADRA2AADRA2BLMNATSHR | |
| Phenformin SCHEMBL10325620 | 0.84 | LMNA (1.00) | HTR3AADRA2AADRA2BLMNATSHR | |
| Phenformin SCHEMBL136512 | 0.84 | LMNA (1.00) | HTR3AADRA2AADRA2BLMNATSHR | |
| SCHEMBL5839538 | 0.83 | HIF1A (0.65) | HTR3AADRA2AADRA2BLMNATSHR | |
| Hydrochloric Acid SCHEMBL10876994 | 0.81 | HIF1A (0.62) | HTR3AADRA2AADRA2BLMNATSHR | |
| Bromide SCHEMBL2282339 | 0.81 | GRIN1 (0.61) | HTR3AADRA2AADRA2BLMNATSHR | |
| SCHEMBL23366564 | 0.81 | TSHR (0.69) | HTR3AADRA2AADRA2BLMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025101904-A1 | NOREPINEPHRINE TRANSPORTER-TARGETED PRODRUGS FOR CANCER THERAPY | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-05-15 | — | — | WO | claimed |
| CN-119950749-A | Polymer-based macromolecular prodrugs | 费城儿童医院 | 2025-05-09 | — | — | CN | claimed |
| US-20220160886-A1 | POLYMER-BASED MACROMOLECULAR PRODRUGS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2022-05-26 | — | — | US | claimed |
| EP-3852793-A1 | POLYMER-BASED MACROMOLECULAR PRODRUGS | The Children's Hospital Of Philadelphia (US) | 2021-07-28 | — | — | EP | claimed |
| CN-112996533-A | Polymer-based macromolecular prodrugs | 费城儿童医院 | 2021-06-18 | — | — | CN | claimed |
| US-20210000967-A1 | POLYMER-BASED MACROMOLECULAR PRODRUGS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2021-01-07 | — | — | US | claimed |
| WO-2020061007-A1 | POLYMER-BASED MACROMOLECULAR PRODRUGS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2020-03-26 | — | — | WO | claimed |
| US-20170190658-A1 | IMAGING AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2017-07-06 | — | — | US | claimed |
| US-7138530-B2 | Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-11-21 | — | — | US | claimed |
| EP-1549632-A4 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | DIMENSIONAL PHARM INC (US) | 2005-11-09 | — | — | EP | claimed |
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | SUBASINGHE NALIN | 2005-10-20 | — | — | US | claimed |
| EP-1549632-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-07-06 | — | — | EP | claimed |
| EP-1032556-A4 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE INC (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | claimed |
| WO-2003099805-A1 | NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| EP-1032556-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 2000-09-06 | — | — | EP | claimed |
| WO-1999020599-A1 | PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE | CAMBRIDGE NEUROSCIENCE, INC. (US) | 1999-04-29 | — | — | WO | claimed |
| US-20250387496-A1 | POLYMER-BASED MACROMOLECULAR PRODRUGS | THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) | 2025-12-25 | — | — | US | disclosed |
| US-4247558-A | HISTAMINE ANTAGONIST | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1981-01-27 | — | — | US | disclosed |
| US-4098898-A | N-SUBSTITUTED-N'-HETEROCYCLIC ALKYLTHIOUREAS, GUANIDINES, AND ANTIHISTAMINES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1978-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234081-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | HTR3A 1132/4885ADRA2A 2350/4885ADRA2B 1456/4885 |
| US-20040009995-A1 | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions | C5, C9, C1R | HTR3A 545/4885ADRA2A 1822/4885ADRA2B 1230/4885 |
| US-20250387496-A1 | POLYMER-BASED MACROMOLECULAR PRODRUGS | PNP, SLC6A19, PTMS | HTR3A 4253/4885ADRA2A 3372/4885ADRA2B 2053/4885 |
| US-20220160886-A1 | POLYMER-BASED MACROMOLECULAR PRODRUGS | PAICS, PNKP, NAMPT | HTR3A 2889/4885ADRA2A 3493/4885ADRA2B 3527/4885 |
| US-20210000967-A1 | POLYMER-BASED MACROMOLECULAR PRODRUGS | PAICS, PNKP, NAMPT | HTR3A 2889/4885ADRA2A 3493/4885ADRA2B 3527/4885 |
| US-20170190658-A1 | IMAGING AGENTS | SLC18A1, VHL, GDI1 | HTR3A 51/4885ADRA2A 153/4885ADRA2B 202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.